HCC share price: The stock dived 7.85 per cent to hit a day low of Rs 38.25. At this price, the scrip has declined 14.67 per cent in four trading days.
Patients with early-stage hepatocellular carcinoma (HCC) and those with advanced-stage disease exhibited distinct gut microbiota diversity and alterations, with future studies warranted to investigate the mechanisms underlying the interactions between gut microbiota and HCC progression.